Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06263673 · ClinicalTrials.gov registry record · Phase 4
Anti-Diabetic Medications to Fight PD and LBD
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
NCT06263673: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT06263673 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06263673, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-05-07 |
| Est. Completion | 2025-01-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06263673
The ClinicalTrials.gov registry entry for NCT06263673 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06263673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06263673 about?
NCT06263673 is a clinical study titled "Anti-Diabetic Medications to Fight PD and LBD". The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.
What is the current status of trial NCT06263673?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2024-05-07. Estimated completion is 2025-01-08.
What interventions are being tested in trial NCT06263673?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT06263673?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.